Mepolizumab reduces moderate to severe COPD exacerbations in patients with varying blood eosinophil counts and type 2 inflammation.

Asthma and COPD share similar breathing symptoms, often leading to confusion and misdiagnosis. Know key differences, risks of ...

Synchrony Medical's LibAirty system for addressing mucus obstruction in COPD patients gained FDA clearance in July 2025.

CEO Barry Quart told investors at Oppenheimer’s 36th Annual Healthcare Life Science Conference that the company is advancing ...

Both dupilumab and mepolizumab were originally approved for asthma but were subsequently studied in patients with COPD who continue to experience symptoms and moderate-to-severe exacerbations despite ...

Inhaled maintenance therapy is underused among hospitalized patients with COPD in China, even in those with frequent prior hospitalizations.

Results showed that a dry powder inhaler loaded with umeclidinium and vilanterol produced a 14% lower risk of moderate or severe COPD flare-ups, compared to a metered-dose inhaler loaded with ...

ABP Live Doc Talk: Most of the patients come into the clinic with complaints of asthma, particularly when they have chronic cough, breathlessness, or wheezing. From a doctor's perspective, a main ...

In an observational study that began enrollment last month, researchers will determine if continuous, remote lung sound ...

New research from UCLA Health suggests that certain inhalers used to treat chronic obstructive pulmonary disease (COPD) are ...

(RTTNews) - GSK plc (GSK) on Friday said the European Commission has approved Nucala as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD). The ...

The decision comes amid declining demand for the company's HPV vaccine Gardasil and only a year after the $1 billion site was announced.